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CLINICAL EVALUATION ON PROPIONYL ERYTHROMYCIN 
LAURYL SULFATE ADMINISTERED TO THE SURGICAL 
PATIENTS IN KEIO HOSPITAL 
Yosi五HARUISHII, TOKIO MAEDA, T AKEHIKO TANAKA, 
HrsA YA lsHrnrKr, HrROYUKI 0HOI 
Surgical Department of Keio University, School~of Medicine. 
Propionyl Erythromycin Laury! sulfate (PELS）よis:_new_type of erythromycin ester. 
We administered PELS to 29 回5白 ofsurgical patients“in our clinic. Results was 
following; 
1) Studies on its_concentration in serum:were done:::reveali昭＿threeto four timぉ
higher level comparing to Erythromycin base. 
2) Culture & Sensitivity tests were performed among 52 strains obtained from the 
infected lesions. Only".4 strains were resistant to PELS. Resistant rate was 7.7%. 
3) Two groups of ,cases were studied clinically, the one was given 200 mg of 
PELS 4 times daily and the other was 300 mg. Only 3 uneffective cas白 werereported. 
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l顔 面 瀦 x 4 5日 有効
2 ， ， 5 ， 
3胸 笠 嫡グ 3 著効
4佼炎創， E年窟織 // 3 ， 
5麦 粒 腫 II 3 ， 
6 肺創急性癌術リ後感染I // 8 
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11 急性乳腺炎 // 3 無効
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